Brief: Kymera Therapeutics Q3 EPS USD -0.94
04/11/2025 12:00
Nov 04 (Reuters) - Kymera Therapeutics Q3 operating expenses USD 95.285 million. Q3 revenue USD 2.764 million vs. IBES estimate USD 19.3 million Q3 net income USD -82.175 million
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer